Atrium Health Levine Cancer Institute | Strategic Alliance Partners

June 27, 2022

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

June 24, 2022

Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.

June 20, 2022

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.

April 14, 2022

New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.

March 30, 2022

February 17, 2022

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

January 28, 2022

Jubilee Brown, MD, discusses recent developments and upcoming trials exploring minimally invasive surgery in ovarian cancer.

January 07, 2022

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

November 02, 2021

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

October 27, 2021

Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

October 05, 2021

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

October 05, 2021

Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.

September 30, 2021

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

September 27, 2021

Jubilee Brown, MD, contextualizes updates in endometrial cancer and cervical cancer, frontline and second-line maintenance, and novel immune-oncology combination strategies in ovarian cancer.

September 09, 2021

August 31, 2021

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

July 07, 2021

Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer and their effect on subsequent treatment decisions, the growth of targeted therapy across gastrointestinal cancers, and expectations for future research and development.

July 01, 2021

Jimmy Hwang, MD, discusses considerations for second-line treatment in gastric/gastroesophageal junction cancer.

June 21, 2021

June 02, 2021

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.